News | Mammography | January 29, 2021

First Mammography Screening Guidelines Issued for Older Survivors of Breast Cancer

A nationwide panel of experts has developed the first mammography guidelines for older survivors of breast cancer, providing a framework for discussions between survivors and their physicians on the pros and cons of screening in survivors' later years.

Getty Images

January 29, 2021 — A nationwide panel of experts has developed the first mammography guidelines for older survivors of breast cancer, providing a framework for discussions between survivors and their physicians on the pros and cons of screening in survivors' later years.

The guidelines, published online in a paper in JAMA Oncology, recommend discontinuing routine mammograms for survivors with a life expectancy under five years; considering stopping screening for those with a 5-10-year life expectancy; and continuing mammography for those whose life expectancy is greater than 10 years. The guidelines will be complemented by printed materials to help survivors gauge their risk of cancer recurring in the breast and weigh the potential benefits and drawbacks of mammography with their healthcare team.

"The standard recommendation for mammography in breast cancer survivors of all ages has been annual screening. There has been little guidance on how to tailor screening for older survivors - what role life expectancy, risk of recurrence, patient preferences, or the tradeoffs associated with mammography should play," said Rachel A. Freedman, M.D., MPH, of Dana-Farber Cancer Institute, the first author of the new paper. "The result is that the use of mammography for older survivors has been highly inconsistent. With the number of older women who will be diagnosed with breast cancer expected to increase in the coming years, it's important that we find ways to individualize decisions for each patient's circumstances and preferences."

To formulate the new guidelines, Freedman recruited an 18-member panel of patients in addition to breast cancer primary care, geriatrics, radiology, survivorship, and nursing experts from around the country to review the scientific literature on the risk of in-breast cancer among older breast cancer survivors, taking into account the subtype of cancer, the treatment patients received, their age, and health status. The group conducted a parallel review of research on the benefits and downsides of mammography. (Designed to detect breast cancer at an early stage, mammograms sometimes uncover growths that turn out not be cancerous, or small, slow-growing tumors that won't have an impact on an older woman's life expectancy. The detection of such growths often entails further stress and anxiety, tests, and treatment.)

Reassuringly, the literature review confirmed that most older breast cancer survivors had a low risk for breast cancer in either breast - particularly for those who had been treated with hormone-blocking therapy for hormone receptor-positive tumors. The panel estimated older survivors' risk of developing cancer in the breast over a 10-year period and organized their results by cancer type and treatment.

The review of mammography studies found that although the benefits of screening in older women are not well defined, research suggests mammography offers little to modest clinical benefit for many older women. The main downsides of mammography were false-positives (detection of growths that appear cancerous but turn out not to be), anxiety associated with diagnostic testing, and overtreatment.

Combining the results of these reviews, the panel formulated a series of mammography guidelines for survivors of breast cancer. The guidelines were considered by a group of clinicians and patient advocates and by five clinician focus groups, resulting in several revisions. After further review by the International Society for Geriatric Oncology, the guidelines were refined and finalized.

Because of the low risk that older survivors will develop a cancer in their breast, the lengthy time needed for the small benefits of mammography to be realized, and the persistence of the negative effects of mammography, the new guidelines recommend discontinuing mammography for breast cancer survivors age 75 or older whose life expectancy is under five years. This holds even for those with a history of higher-risk tumors such as triple-negative or ERBB2-positive. (Life expectancy is estimated by factors such as an individual's medical history, their degree of functional independence, whether they smoke cigarettes, had a fall in the previous year, and whether they were recently hospitalized.) The guidelines call for consideration of stopping mammography when life expectancy is five to 10 years and continuing annual or biennial mammography when life expectancy exceeds 10 years. For women age 85 and older, whose life expectancy is often under five years, the guidelines recommend ceasing mammography unless an individual is in extraordinary health and has a strong preference to continue testing.

Freedman emphasizes that the new guidelines are not prescriptive but should serve as a starting point for older survivors of breast cancer in conversations with their physician. "The purpose of the guidelines is to offer clinicians support for having these conversations with patients and to make a shared, individualized decision for each woman," she said.

For more information: www.dfci.harvard.edu

Related Content

55-year-old woman who underwent screening mammogram and ultrasound 7 days after first COVID-19 vaccination dose. Screening mammogram and US demonstrated unilateral left axillary lymph node with cortical thickness of 5 mm on ultrasound (not shown). BI-RADS category 0 was assigned. Ultrasound from diagnostic work-up performed 7 days later showed no change in lymph node size. BI-RADS 3 was assigned. #COVIDvaccine #COVID19

55-year-old woman who underwent screening mammogram and ultrasound 7 days after first COVID-19 vaccination dose. Screening mammogram and US demonstrated unilateral left axillary lymph node with cortical thickness of 5 mm on ultrasound (not shown). BI-RADS category 0 was assigned. Ultrasound from diagnostic work-up performed 7 days later showed no change in lymph node size. BI-RADS 3 was assigned.

News | Breast Imaging | February 24, 2021
F-18 FES PET images of patients with ER+/PR+/HER2- invasive ductal carcinoma. Left panel: Progressive disease seen at the 8-week time-point in a patient on sequential therapy. Right panel: Stable disease through all 3 time-points, remaining on study therapy for 6.7 months until disease progression on combined vorinostat aromatase inhibitor therapy. Image created by Lanell M Peterson, Research Scientist, University of Washington Medical Oncology, Seattle WA.

F-18 FES PET images of patients with ER+/PR+/HER2- invasive ductal carcinoma. Left panel: Progressive disease seen at the 8-week time-point in a patient on sequential therapy. Right panel: Stable disease through all 3 time-points, remaining on study therapy for 6.7 months until disease progression on combined vorinostat aromatase inhibitor therapy. Image created by Lanell M Peterson, Research Scientist, University of Washington Medical Oncology, Seattle WA.

News | Molecular Imaging | February 22, 2021
February 22, 2021 — Molecular imaging
Examples of the imaging performance of XPCI-CT (b,e) compared to conventional specimen radiography (a,d) and benchmarked against histopathology (c,f). he top row focuses on the similarity between the XPCI-CT slice in (b) and the histological slice in (c). Arrow 1 indicates margin involvement, arrow 2 a variation in density in the internal structure of the tumour mass, arrow 3 tumour-induced inflammation. All this is confirmed by the histological slice in (c), and hardly visible in the conventional image in

Examples of the imaging performance of XPCI-CT (b,e) compared to conventional specimen radiography (a,d) and benchmarked against histopathology (c,f). he top row focuses on the similarity between the XPCI-CT slice in (b) and the histological slice in (c). Arrow 1 indicates margin involvement, arrow 2 a variation in density in the internal structure of the tumour mass, arrow 3 tumour-induced inflammation. All this is confirmed by the histological slice in (c), and hardly visible in the conventional image in (a). The bottom row focuses on the detection of small calcifications, a key feature in DCIS. These are undetectable in (d), detected in (e), enhanced in the maximum intensity projection (MIP) image at the bottom of (f), and confirmed by histopathology in the top part of (f). The scale bar [shown in (b) and (e)] is the same for all images apart from (f), which has its own scale. Red arrows in (e) and (f) indicate the microcalcifications. Image courtesy of Professor Alessandro Olivo

News | Breast Imaging | February 22, 2021
February 22, 2021 — A new X-ray imaging scanne
A comparison of standard mammography imaging (left) in a woman with dense breasts and a breast MRI imaging study (right) showing a clearly defined cancer and is extremely hard to detect on the mammograms.

A comparison of standard mammography imaging (left) in a woman with dense breasts and a breast MRI imaging study (right) showing a clearly defined cancer and is extremely hard to detect on the mammograms. Images from Christiane Kuhl, M.D.

Feature | MRI Breast | February 17, 2021 | By Dave Fornell, Editor
Dense breast tissue can hide cancers i
Screening strategy based on baseline breast density at age 40 may be effective and cost-effective for reducing breast cancer mortality

Getty Images

News | Breast Density | February 10, 2021
February 10, 2021 — A mammography screenin...
Comparison of breast cancer mortality rates (red squares) and distant-stage breast cancer incidence rates from SEER9 (blue dots) and SEER18 (green dots) per 100,000 for white women aged, A, 20–39, B, 40–69, and, C, 70–79 years (3,7,8).

Comparison of breast cancer mortality rates (red squares) and distant-stage breast cancer incidence rates from SEER9 (blue dots) and SEER18 (green dots) per 100,000 for white women aged, A, 20–39, B, 40–69, and, C, 70–79 years (3,7,8). Image courtesy of Radiology 

News | Breast Imaging | February 10, 2021
February 10, 2021 — Breast cancer death rates have stopped declining for women in the U.S.
After acquiring the molecular breast imaging (MBI) assets from GE Healthcare and Dilon Technologies, Inc., SmartBreast Corporation (SmartBreast), a privately held company focused on breast cancer screening and diagnosis, announced today that it has formed a partnership with FoxSemicon Integrated Technologies, Inc. (FITI) to manufacture molecular breast imaging (MBI) systems.
News | Breast Imaging | February 09, 2021
February 9, 2021 — After acquiring the...

Chart courtesy of the American Cancer Society

News | Breast Imaging | February 08, 2021
February 8, 2021 — Cancer ranks as a leading cause of death in every country in the world, and, for the first time,
Volpara Health, a health technology software company whose integrated breast care platform assists in the delivery of personalized patient care, announced the acquisition of CRA Health, LLC, a breast cancer risk assessment company spinoff from Massachusetts General Hospital — a Harvard Medical School teaching hospital.

Getty Images

News | Breast Imaging | February 02, 2021
February 2, 2021 — Volpara Health, a health technology software company whose integrated...